Treg A and B markers and summary of changes in AA
| Treg subpopulation . | Markers . | Healthy donors . | IST responder AA pretreatment . | IST nonresponder AA pretreatment . | IST responder AA posttreatment . | IST nonresponder AA posttreatment . |
|---|---|---|---|---|---|---|
| Treg A | CD45RA↑ CD7↑ CD27↑ CCR4↓ CCR6↓ CD25↓* CD28↓ CD45RO↓CD95↓ CXCR3↓ FOXP3↓* HLA-DR↓ | Minor population | ↑38.8% ± 5.0% | ↑↑ 63.5% ± 4.5% | ↓19.26% ± 2.43% | NSC |
| 20.3% ± 6.6% | 73.9% ± 6.8% | |||||
| Treg A (TNF-a+) | TNF-α + IL-10↓ | R | NSC | NSC | ↓0.32% ± 0.12% | NSC |
| CD279↓ | 1.2% ± 0.3% | 0.75% ± 0.14% | 0.79% ± 0.13% | 1.81% ± 0.19% | ||
| HLA-DR↓ CD38↓ | ||||||
| Treg B | CD45RA↓ CD7↓ CD27↓ CCR4↑ CCR6↑ CD25↑† CD28↑ CD45RO↑CD95↑ CXCR3↑ FOXP3↑† | Major population 72.2% ± 6.7% | ↓48.8% ± 6.1% | ↓↓ 28.9% ± 2.7% | NSC 59.98% ± 3.18% | NSC 21.8% ± 4.3% |
| HLA-DR↑ |
| Treg subpopulation . | Markers . | Healthy donors . | IST responder AA pretreatment . | IST nonresponder AA pretreatment . | IST responder AA posttreatment . | IST nonresponder AA posttreatment . |
|---|---|---|---|---|---|---|
| Treg A | CD45RA↑ CD7↑ CD27↑ CCR4↓ CCR6↓ CD25↓* CD28↓ CD45RO↓CD95↓ CXCR3↓ FOXP3↓* HLA-DR↓ | Minor population | ↑38.8% ± 5.0% | ↑↑ 63.5% ± 4.5% | ↓19.26% ± 2.43% | NSC |
| 20.3% ± 6.6% | 73.9% ± 6.8% | |||||
| Treg A (TNF-a+) | TNF-α + IL-10↓ | R | NSC | NSC | ↓0.32% ± 0.12% | NSC |
| CD279↓ | 1.2% ± 0.3% | 0.75% ± 0.14% | 0.79% ± 0.13% | 1.81% ± 0.19% | ||
| HLA-DR↓ CD38↓ | ||||||
| Treg B | CD45RA↓ CD7↓ CD27↓ CCR4↑ CCR6↑ CD25↑† CD28↑ CD45RO↑CD95↑ CXCR3↑ FOXP3↑† | Major population 72.2% ± 6.7% | ↓48.8% ± 6.1% | ↓↓ 28.9% ± 2.7% | NSC 59.98% ± 3.18% | NSC 21.8% ± 4.3% |
| HLA-DR↑ |
Surface and intracellular markers that are significantly higher or lower in Treg subpopulations as well as their frequencies in HD, IST responder, and nonresponder AA patients before and after IST.
NSC, no significant change; R, reference value.
Lower expression compared with Treg B subpopulation.
Higher expression compared with Treg A subpopulation.